姚記科技(002605.SZ):上海細胞治療集團完成D1輪融資 公司持其11.45%股權
格隆匯5月28日丨姚記科技(002605.SZ)公佈,上海細胞治療集團有限公司(“細胞公司”)為公司的參股公司,前身為上海細胞治療工程技術研究中心集團有限公司,細胞公司是一傢俱有細胞治療研發中心、細胞生產中心及細胞治療臨牀應用中心為一體,具有顯著轉化醫學特徵的細胞治療工程技術公司,該公司一方面為細胞治療的臨牀應用提供高效、特異、安全的細胞治療產品,另一方面根據臨牀需求,開發更為先進的細胞治療產品、技術及生產工藝。
2021年4月,細胞公司啟動D1輪融資,本輪融資細胞公司獲得長三角(上海)產業創新股權投資基金合夥企業(有限合夥)、建銀國際資產管理(上海)有限公司、常州九洲創星創業投資合夥企業(有限合夥)、嘉興海晟股權投資合夥企業(有限合夥)、上海吉量經濟發展中心(有限合夥)、上海蕭稍經濟發展中心(有限合夥)等合計4.307億元的投資。本輪融資,公司並未出資,此輪融資完成後,細胞公司估值為69.307億元,公司持有其11.45%股權。
目前,公司與各股東已按照約定簽訂《關於上海細胞治療集團有限公司之增資協議》,辦理完成了股權轉讓工商變更登記手續,並2021年5月28日領取了換髮後的《營業執照》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.